Early aggressive macrovascular disease and type 1 diabetes mellitus without chronic complications: A case report

被引：5
作者：
Saldanha De Mattos Matheus A. [1 ]
Brito Gomes M. [1 ]
机构：
[1] Diabetes Unit, State University of Rio de Janeiro, Rio de Janeiro
来源：
BMC Research Notes | / 6卷 / 1期
关键词：
Cardiovascular risk; Coronary artery disease; Diabetes mellitus; Macrovascular complications; Type; 1;
D O I：
10.1186/1756-0500-6-222
中图分类号：
学科分类号：
摘要：
Background: Type 1 diabetes (T1DM) is considered to be one of the most significant risk factors for the development of coronary artery disease (CAD). However, the specific risk predictor models for T1DM are subject to many limitations. Case presentation. We report the case of a 42-year-old Caucasian woman presenting with T1DM for 26 years. During her chronic hyperglycemic evolution (mean of HbA1c > 3 percentage points above the superior limit) without microvascular complications, this patient presented with early and aggressive coronary artery disease, despite the lack of classical risk factors for CAD. Conclusions: The rapidly progressive macrovascular disease observed in this case demonstrates the different degrees of aggressiveness and unpredictable clinical evolution observed in some cases. It also confirms the need for a multi-factorial, early and optimized clinical management regime. © 2013 Saldanha de Mattos Matheus and Brito Gomes; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 33 条
  • [21] Franklin K., Goldberg R.J., Spencer F., Klein W., Budaj A., Brieger D., Implications of diabetes in patients with acute coronary syndromes. The global registry of acute coronary events, Arch Intern Med, 64, pp. 1457-1463, (2004)
  • [22] Costacou T., Ferrell R.E., Orchard T.J., Haptoglobin genotype: A determinant of cardiovascular complication risk in type 1 diabetes, Diabetes, 57, pp. 1702-1706, (2008)
  • [23] Vardi M., Blum S., Levy A.P., Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus- natural history of the disease and the effect of vitamin e treatment. Meta-analysis of the medical literature, Eur J Intern Med, 23, 7, pp. 628-632, (2001)
  • [24] Soderlund J., Forsblom C., Ilonen J., Thorn L.M., Waden J., Parkkonen M., Groop P.H., Study Group F., HLA class II is a factor in cardiovascular morbidity and mortality rates in patients with type 1 diabetes, Diabetologia, 55, 11, pp. 2963-2969, (2012)
  • [25] Natarajan S., Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease, Arch Intern Med, 163, pp. 1735-1740, (2003)
  • [26] Laing S.P., Swerdlow A.J., Slater S.D., Burden A.C., Morris A., Waugh N.R., Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes, Diabetologia, 46, pp. 760-765, (2003)
  • [27] Cobas R.A., Type 1 diabetic patients evolution to hypertension, Arq Bras Endocrinol Metab, 52, 4, pp. 628-634, (2008)
  • [28] Mosca L., Appel L.J., Benjamin E.J., Berra K., Chandra-Strobos N., Fabunmi R.P., Evidence-based guidelines for cardiovascular disease prevention in women. American heart association scientific statement, Arteriosclerosis Thromb Vasc Biol, 24, (2004)
  • [29] Douglas P.S., Ginsburg G.S., The evaluation of chest pain in women, N Engl J Med, 334, pp. 1311-1315, (1996)
  • [30] Mosca L., Grundy S.M., Judelson D., King K., Limacher M., Oparil S., Guide to preventive cardiology for women. AHA/ACC scientific statement consensus panel statement, Circulation, 99, pp. 2480-2484, (1999)
1234